Santibanez Juan F, Bjelica Suncica
Group for Molecular Oncology, Institute for Medical Research, University of Belgrade, Dr. Subotica 4, 11129 Belgrade, Serbia.
Centro Integrativo de Biología y Química Aplicada (CIBQA), Universidad Bernardo O'Higgins, General Gana 1780, Santiago 8370854, Chile.
Recent Pat Anticancer Drug Discov. 2018;13(2):133-144. doi: 10.2174/1574892813666180220105958.
IL-17A is a founding member of the IL-17 family that has been implicated in the pathogenesis of inflammatory-associated diseases such as cancer and autoimmune disease. In cancer, IL-17A participates in many key events for tumor development, in part by affecting innate and adaptive immune system and also by direct modulation of many pro-tumor events. Moreover, IL-17A dysregulation at the site of inflammation is associated with rheumatoid arthritis, multiple sclerosis, psoriasis, among others. IL-17A has emerged as a topic of interest and is under profound investigation for its involvement in several types of inflammatory-associated diseases.
This review aims to present an overview of the state of the art of IL-17A role in cancer and inflammation, as well as to describe recent patents targeting IL-17A with relevant clinical and biological properties for the prevention and treatment of cancer and inflammatory diseases.
Relevant information was obtained by searching in PubMed using IL-17A or IL-17, cancer and inflammation as keywords, while relevant patents were obtained mainly from Google Patents.
Literature data indicated IL-17A as important biomolecule in the physiopathology of cancer and inflammatory diseases. Whereas, novel patents (2010 to 2017) targeting IL-17A are focused mainly on describing strategies to modulate IL-17A per se, co-modulation by bispecific antibodies to blocking IL-17A and important cytokines for IL-17A functions, upstream mechanisms and compounds to regulate IL-17A expression.
The promising effects of patented agents against IL-17A may open new opportunities to therapeutic intervention targeting at different levels of involvement in the pathogenesis of cancer and inflammatory diseases.
白细胞介素-17A（IL-17A）是白细胞介素-17家族的创始成员，与癌症和自身免疫性疾病等炎症相关疾病的发病机制有关。在癌症中，IL-17A参与肿瘤发展的许多关键事件，部分是通过影响先天性和适应性免疫系统，也通过直接调节许多促肿瘤事件。此外，炎症部位的IL-17A失调与类风湿性关节炎、多发性硬化症、牛皮癣等疾病有关。IL-17A已成为一个受关注的话题，并因其参与多种炎症相关疾病而受到深入研究。
本综述旨在概述IL-17A在癌症和炎症中的作用的最新进展，并描述针对IL-17A的具有相关临床和生物学特性的近期专利，用于预防和治疗癌症及炎症性疾病。
通过在PubMed中使用IL-17A或IL-17、癌症和炎症作为关键词进行搜索来获取相关信息，而相关专利主要从谷歌专利中获得。
文献数据表明IL-17A是癌症和炎症性疾病生理病理学中的重要生物分子。而针对IL-17A的新型专利（2010年至2017年）主要集中在描述调节IL-17A本身的策略、通过双特异性抗体共同调节以阻断IL-17A和对IL-17A功能重要的细胞因子、调节IL-17A表达的上游机制和化合物。
针对IL-17A的专利药物的有前景的效果可能为针对癌症和炎症性疾病发病机制不同参与水平的治疗干预开辟新机会。
